NASDAQ · OBIO
Orchestra BioMed Holdings, Inc.
$6.09+$0.10 (+1.67%)
Orchestra BioMed Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.31% below the high.
Loading market information…
NASDAQ · OGI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Organigram Global Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Organigram Global Inc.’s next earnings report is currently expected on Dec 15, 2026, with estimated earnings per share of $0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Organigram Global Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Organigram Global Inc., primarily operating through its subsidiary Organigram Holdings Inc., is a Canadian enterprise specializing in the cultivation, production, and distribution of cannabis and related products. The company serves the medical cannabis market by offering products such as cannabis flowers, oils, and vaporizing devices to both civilian patients and military veterans. For adult recreational consumers, Organigram provides a diverse range of cannabis products, including edibles and concentrates, under popular brands like Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour. Additionally, the company acts as a wholesale supplier, distributing cannabis plant cuttings, dried flowers, proprietary blends, pre-rolled products, and various cannabis derivatives to retailers and other wholesalers within the adult-use recreational sector. Customers can purchase Organigram's offerings through its online platform or via telephone orders. Established in 2013, the company's corporate headquarters are located in Moncton, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | May 12, 2025 | $0.22+841.0% vs estimate | $45.58M+7.06% vs estimate |
|---|
| Q1 2025 | Feb 11, 2025 | -$0.14-363.27% vs estimate | $29.69M-10.81% vs estimate |
|---|
| Q4 2024 | Dec 18, 2024 | -$0.04-33.33% vs estimate | $33.03M+1.64% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.09+$0.10 (+1.67%)
Orchestra BioMed Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.31% below the high.
$14.45+$0.13 (+0.91%)
InfuSystem Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.23% below the high.
$4.08$0.00 (0.0%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.85% below the high.
$6.52+$0.01 (+0.15%)
Lifecore Biomedical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.39% below the high.
$27.68+$0.40 (+1.47%)
Electromed, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.6% below the high.
$6.75+$0.06 (+0.9%)
Cartesian Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.65% below the high.
$3.73+$0.02 (+0.54%)
Inventiva S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.83% below the high.
$5.41+$0.29 (+5.66%)
Journey Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 43.41% below the high.
